Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Buffer Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

TY800 Dose Escalation (Typhoid)

NCT00269295
View directory record Official record
Conditions
Typhoid and Paratyphoid Fevers
Interventions
Ty800, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 25, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 25, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

NCT06007183
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
CHIKV VLP vaccine booster, Placebo booster
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
12 Years and older
Enrollment
715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
24
States / cities
Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

NCT00561470
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasm Metastasis
Interventions
Placebo, Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
87
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer

NCT00004038
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad5CMV-p53 gene, chemotherapy
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

NCT01266850
View directory record Official record
Conditions
Rotavirus Infection
Interventions
Rotarix®, RotaTeq®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Weeks to 14 Weeks
Enrollment
1,384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
13
States / cities
Oakland, California • Atlanta, Georgia • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 3 Interventional Results available

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NCT03113760
View directory record Official record
Conditions
NLRC4-MAS, XIAP Deficiency
Interventions
Tadekinig alfa, 0.9% sodium chloride
Drug · Other
Lead sponsor
AB2 Bio Ltd.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Closed Eye Neutrophils in Dry Eye Disease

NCT03332342
View directory record Official record
Conditions
Dry Eye, Ocular Inflammation
Interventions
Eye wash
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 25, 2026, 6:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamics of SYNB1020

NCT03447730
View directory record Official record
Conditions
Cirrhosis
Interventions
SYNB1020, Placebo
Drug · Other
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 74 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Coronado, California • Rialto, California • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA

NCT01033409
View directory record Official record
Conditions
Pneumonia
Interventions
Salmonella Typhi-vectored pneumonia vaccine
Biological
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 25, 2026, 6:54 AM EDT
Terminated Phase 3 Interventional

Ga-68-PSMA-11 in Men With Prostate Cancer

NCT05744115
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Ga-68-PSMA-11
Drug
Lead sponsor
Timothy Hoffman
Federal
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 25, 2026, 6:54 AM EDT
Available No phase listed Expanded access

Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS

NCT05281484
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

NCT00767416
View directory record Official record
Conditions
Healthy
Interventions
MEDI-559, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
75
States / cities
Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 25, 2026, 6:54 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT07408583
View directory record Official record
Conditions
Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure Disorders, Genetic Diseases, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders, Cancer Predisposition Syndrome
Interventions
IUHSCT for FA-affected fetuses
Biological
Lead sponsor
Agnieszka Czechowicz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2033
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

NCT01667341
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 with Matrix M-2, GEN-003, Placebo
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 25, 2026, 6:54 AM EDT
Terminated Phase 2 Interventional Results available

Haploid Allogeneic Transplant Using the CliniMACS System

NCT00185679
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) - Refractory
Interventions
CliniMACS System
Device
Lead sponsor
Ginna Laport
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 25, 2026, 6:54 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 25, 2026, 6:54 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 6:54 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259308
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
62
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 25, 2026, 6:54 AM EDT
No Longer Available No phase listed Expanded access

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

NCT02258490
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
G-CSF mobilized CD34+ selected cells for transplantation
Biological
Lead sponsor
Emory University
Other
Eligibility
17 Years to 75 Years
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 25, 2026, 6:54 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents

NCT01843491
View directory record Official record
Conditions
Healthy, Malaria
Interventions
Ad-PfCA
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

NCT02419391
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA BN RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 25, 2026, 6:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

NCT03300050
View directory record Official record
Conditions
Influenza, Vaccine
Interventions
cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 6:54 AM EDT